S989 Outcomes of Patients Admitted With Acute, Severe Ulcerative Colitis on Established Biologic Therapy: A Retrospective Analysis from a Tertiary Referral Hospital
Pourquoi ce travail est dans la base
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Notice bibliographique
Résumé
Introduction: Acute, severe, ulcerative colitis (ASUC) is a phenotype of UC that is associated with significant morbidity. In steroid refractory ASUC, salvage medical therapy with infliximab is recommended to reduce the risk of colectomy. However, the evidence supporting this practice is based on cohorts naïve to biologics. Consequently, the management of patients on established biologic or small molecule therapy (EBST) with ASUC is not well defined. Methods: We conducted a retrospective chart review of patients admitted with ASUC to Mount Sinai Hospital (MSH) in Toronto, Ontario from January 2018 until January 2022. Included subjects were considered to be on EBST if they had received a dose of these agents within 56 days prior to admission. Our primary outcome was the mean difference in hospital length of stay (HLOS) between the 2 groups. Additional outcomes of interest include rates of surgical consultation, rates of inpatient colectomies, and 90-day readmission rates. Results: Of the 185 admission for ASUC, 76 were on EBST and 109 were not. Baseline characteristics were similar between the 2 groups. There were no significant differences in hospital length of stay (7.46 days vs 7.45 days p = 0.52) or in-hospital colectomy rates between the 2 groups. Patients on EBST had higher rates of surgical consultation (36.8% vs 8.3% P< 0.01) prior to discharge and 90-day readmission rates (26.3% vs 13.8% p = 0.03). Conclusion: Patients on EBST were more likely to receive a surgical consultation during their admission and had higher rates of readmission at 90 days. ASUC remains a challenging clinical entity to manage and further studies evaluating the underlying factors that contribute to readmission in patients on EBST in hospital are needed (Figure 1, Table 1).Figure 1.: Comparison of duration of intravenous steroids and hospital length of stay in patients on EBST vs not on EBST. Table 1. - Baseline characteristics and admission severity Not established (N=109) Established (N= 76) P value Patient characteristics Age (years) 34.9 (SD 11.8) 31.5 (SD 11.6) 0.05 Males 43 (39.5%) 41 (54.0%) 0.07 Current tobacco use 5 (4.6%) 3 (4.0%) 1.0 Current alcohol use 38 (34.9%) 25 (32.9%) 0.90 Disease duration (years) 6.2 (SD 7.4) 5.4 (SD 5.3) 0.43 UC flare requiring admission within 1 year 20 (18.4%) 35 (46.1%) < 0.01 Baseline medication use 5-ASA use 63 (57.8 %) 19 (25.0%) < 0.01 Immunomodulator use (AZA/MTX) 4 (3.7%) 16 (21.0%) < 0.01 Previous anti-TNF therapy 13 (11.9%) 28 (36.8%) < 0.01 Previous Vedolizumab therapy 3 (2.8%) 13 (17.1%) < 0.01 Previous Ustekinumab therapy 0 (0%) 1 (1.3%) 0.90 Previous Tofacitinib therapy 0 (0%) 0 (0%) N/A Exposure to ≥ 2 biologics 4 (3.7%) 29 (38.2%) < 0.01 Admission severity Bowel movements ≥ 10 per day 75 (70.7%) 66 (86.8%) 0.02 Systolic blood pressure ≤ 100 mmHg 37 (33.9%) 22 (28.9%) 0.58 Heart rate ≥ 100 bpm 64 (58.7%) 39 (51.3%) 0.40 Temperature ≥ 38.0 Celsius 24 (22.0%) 15 (19.7%) 0.85 CRP (mg/L) 67.4 (SD 62.4) 41.8 (SD 50.1) < 0.01 Hemoglobin (g/L) 118.2 (SD 23.5) 113.3 (SD 22.6) 0.16 White blood cell count (109/L) 11.6 (SD 3.9) 10.9 (SD 5.2) 0.32 Current biologic in patients on established biologic therapy (N=76) Infliximab 36 (47.4%) Golimumab 5 (6.6%) Adalimumab 8 (10.5 %) Vedolizumab 20 (26.3%) Ustekinumab 6 (7.9%) Tofacitinib 1 (1.3%)
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,001 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle